• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Paradigm shift in cancer treatment to targeted therapies

byCaitlyn HuiandDeepti Shroff Karhade
July 31, 2018
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. HER2 targeted breast cancer treatment has significantly improved prognosis.

2. Novel immune checkpoint therapies have resulted in considerable clinical response for a variety of cancer types.

Evidence Rating Level: 2 (Good)

Study Rundown: Cancer therapy is a continually evolving field, as researchers strive to determine the most effective methods of treating this complex disease. One of the mainstays of cancer treatment is cytotoxic chemotherapy, a relatively nonselective treatment that results in cell death of cancerous—and potentially noncancerous—tissues. One of the rising new treatments in cancer treatment is targeted therapy, which refers to preferentially targeting cancer cells. The authors of this study wrote a review providing an overview of the landscape of current tissue-agnostic cancer therapy treatments and the future of cancer therapy. One of the limitations of this review was that some of the treatments mentioned are currently in clinical trials and the results are pending the completion of these trials. Overall, this review provided a strong overview of different types of targeted cancer therapies for lung cancer, gastroesophageal cancer, and breast cancer, among other cancer types.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Precision medicine becomes reality— tumor type-agnostic therapy

RELATED REPORTS

Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

Oral semaglutide reduces cardiovascular event rates in high-risk patients

In-Depth [review]: The authors of this study wrote a review of current targeted cancer treatments available and in trial. They provided an overview of specific types of tissue-agnostic treatments for various cancer types, as well as described some of the trial designs and overall theories behind targeted therapy. Generally, the authors described three biomarkers, BRAF V600, HER2, and BRCA1/2 mutation, with respect to therapeutic cancer targets and treatment approaches. BRAF plays an important role in lung cancer and cutaneous melanoma. The authors addressed that studies have shown improved outcomes in survival for patients with the BRAF mutation undergoing targeted treatment. Similar results were observed for other cancer types as well.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Comparative analysis of wounds from oral mucosa versus skin reveals novel therapeutic targets for rapid wound healing [PreClinical]

Next Post

Hospital admission linked to reduced quality and quantity of sleep

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Emergency

Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis

June 5, 2025
Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Cardiology

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

June 5, 2025
Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Oral semaglutide reduces cardiovascular event rates in high-risk patients

June 5, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

June 4, 2025
Next Post

Hospital admission linked to reduced quality and quantity of sleep

Amyloidogenic genetic variant not associated with increased mortality in blacks

Patisiran is effective in treatment of hereditary transthyretin amyloidosis.

Early in-bed cycling and electrical stimulation no different than standard rehabilitation for global muscle strength in ICU patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.